Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment

뉴스 본문을 불러오고 있어요.

Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment | 웨이프 WAPE

Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment

기사 요약

관련 종목

댓글 —